|
|
Article: Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind™.
- Article from:
- Biotech Week
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PBO) has announced that it has entered into a non-binding letter of intent with BioTechnology Consulting Poland Sp. z.o.o. to license its Pulmonary Vascular Diagnostic Product Candidate PulmoBind™ for development work, clinical trials and ultimately, commercialization in the European market (see also Biotechnology).
"We are very pleased to have signed a non-binding LOI with BioTechnology Consulting Poland. The license agreement contemplated by the LOI will allow Pulmo BioTech to continue with its focus on achieving regulatory approval for PulmoBind in North America while ensuring that European ...